Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine - FLU-02-IB

NCT02819180 | Completed

• 1 other identifier: FLU-02-IB
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

Prospective cohort study to evaluate the safety and immunogenicity of the Butantan Influenza vaccine (Fragmented and Inactivated) among healthy adults with 18 to 59 years of age and elderly older than 60 years of age.

Conditions

Influenza

Keywords

Influenza

Outcome Measures

Primary Outcomes (2)

• Adverse events in the first 3 days post vaccination (Safety)

  Solicited and unsolicited local and systemic adverse reactions reported by the participants until Day 3 after vaccination.

  Three days

• Antibody response to each of the vaccine strains 21 days post vaccination (Immunogenicity)

  Antibody response to each of the vaccine´s strains as measured by: * % seroconversion and/or * increase in the geometric mean of hemagglutination inhibition (HAI) titers and/or * % seroprotection.

  21 days

Study Arms (2)

Healthy adults group

Healthy men and women between 18 and 59 years of age.

Biological: Butantan Influenza Trivalent, Fragmented and Inactivated vaccine

Elderly group

Elderly over 60 years old.

Biological: Butantan Influenza Trivalent, Fragmented and Inactivated vaccine

Interventions

Butantan Influenza Trivalent, Fragmented and Inactivated vaccine BIOLOGICAL

Also known as: Butantan Influenza vaccine

Elderly group; Healthy adults group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Health adults with age between 18 and 59 years, as well as elderly over 60 years of age may participate in the study. To be included in the study, participants need to meet all inclusion criteria, and not fulfill any exclusion criteria.

You may qualify if:

• Healthy adults, male or female aged 18 to 59
• Elderly aged 60 years completed and above
• To be available to participate in the study throughout its duration (approximately 21 days)
• To have medical indication to be vaccinated against influenza
• To demonstrate intention to participate in the study, as documented by signature in the study´s informed consent form.

You may not qualify if:

• Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as clinical history and/or physical examination (except hypertension under control among the elderly)
• Compromised immune system diseases including: HIV, diabetes mellitus, cancer (except basal cell carcinoma) and autoimmune diseases
• Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements
• Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history
• Known systemic hypersensitivity to eggs or to any component of the vaccine
• History of severe adverse reaction after previous administration of an Influenza vaccine within 6 weeks following vaccination

Sponsors & Collaborators

• Butantan Institute: lead

Study Sites (1)

Centro de Referência de Imunobiológicos Especiais (CRIE) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

São Paulo, São Paulo, Brazil

Location

Related Publications (1)

• Mondini G, Braga PE, Lopes MH, Sartori AMC, Miyaji KT, Infante V, Randi BA, Timenetsky MDCST, Ferreira JCOA, Sakita NK, Precioso AR. Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan. Rev Inst Med Trop Sao Paulo. 2018 Jul 30;60:e37. doi: 10.1590/S1678-9946201860037.

  PMID: 30066805 DERIVED

MeSH Terms

Conditions

Influenza, Human

Interventions

Vaccines, Inactivated

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Vaccines; Biological Products; Complex Mixtures

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 28, 2016
• First Posted: June 30, 2016
• Study Start: April 1, 2014
• Primary Completion: June 1, 2014
• Study Completion: June 1, 2014
• Last Updated: June 30, 2016

Record last verified: 2016-06

Locations

BR (1)